Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.

Trial Details

NCT ID

NCT05272826

Phase

PHASE2

Sponsor

Canadian Myeloma Research Group

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

Iberdomide
Bortezomib
Dexamethasone
Isatuximab

Locations (sample)

Edmonton, Alberta, Canada|53.55014,-113.46871
St. John's, Newfoundland and Labrador, Canada|47.56494,-52.70931
Halifax, Nova Scotia, Canada|44.64269,-63.57688
London, Ontario, Canada|42.98339,-81.23304
Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

Must understand and voluntarily sign informed consent form
Age ≥ 65 years at the time of signing consent
Must be able to adhere to the study visit schedule and other protocol requirements.
Previously untreated, transplant ineligible, symptomatic multiple myeloma as defined by the criteria below.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →